1. <span id="izpls"></span>

    Boji Medical Technology Co., Ltd.
    Boji Medical Technology Co., Ltd.(Boji for short, stock code: 300404), founded in 2002 and listed in Shenzhen GEM in 2015.
    Boji Medical Technology Co., Ltd.
    Boji Medical Technology Co., Ltd. (Boji for short, stock code: 300404), founded in 2002 and listed in Shenzhen GEM in 2015.
    Boji Medical Technology Co., Ltd.
    Boji Medical Technology Co., Ltd. (Boji for short, stock code: 300404), founded in 2002 and listed in Shenzhen GEM in 2015.
    Boji Medical Technology Co., Ltd.
    Boji Medical Technology Co., Ltd.(Boji for short, stock code: 300404), founded in 2002 and listed in Shenzhen GEM in 2015.
    Boji Medical Technology Co., Ltd.
    Boji Medical Technology Co., Ltd.(Boji for short, stock code: 300404), founded in 2002 and listed in Shenzhen GEM in 2015.
    Boji Medical Technology Co., Ltd.
    Boji Medical Technology Co., Ltd. (Boji for short, stock code: 300404), founded in 2002 and listed in Shenzhen GEM in 2015.
    Boji Medical Technology Co., Ltd.
    Boji Medical Technology Co., Ltd.(Boji for short, stock code: 300404), founded in 2002 and listed in Shenzhen GEM in 2015.
    "One-stop" services for drug development include new drug project research and activity screening, pharmaceutical research (including pilot production), pharmacology and toxicology research, production of clinical drugs and agent simulatant, clinical trials, clinical data management and statistical analysis, post-market evaluation.
    "One-stop" services for drug development include new drug project research and activity screening, pharmaceutical research (including pilot production), pharmacology and toxicology research, production of clinical drugs and agent simulatant, clinical trials, clinical data management and statistical analysis, post-market evaluation.
    "One-stop" services for drug development include new drug project research and activity screening, pharmaceutical research (including pilot production), pharmacology and toxicology research, production of clinical drugs and agent simulatant, clinical trials, clinical data management and statistical analysis, post-market evaluation.
    "One-stop" services for drug development include new drug project research and activity screening, pharmaceutical research (including pilot production), pharmacology and toxicology research, production of clinical drugs and agent simulatant, clinical trials, clinical data management and statistical analysis, post-market evaluation.
    "One-stop" services for drug development include new drug project research and activity screening, pharmaceutical research (including pilot production), pharmacology and toxicology research, production of clinical drugs and agent simulatant, clinical trials, clinical data management and statistical analysis, post-market evaluation.
    "One-stop" services for drug development include new drug project research and activity screening, pharmaceutical research (including pilot production), pharmacology and toxicology research, production of clinical drugs and agent simulatant, clinical trials, clinical data management and statistical analysis, post-market evaluation.
    "One-stop" services for drug development include new drug project research and activity screening, pharmaceutical research (including pilot production), pharmacology and toxicology research, production of clinical drugs and agent simulatant, clinical trials, clinical data management and statistical analysis, post-market evaluation.
    "One-stop" services for drug development include new drug project research and activity screening, pharmaceutical research (including pilot production), pharmacology and toxicology research, production of clinical drugs and agent simulatant, clinical trials, clinical data management and statistical analysis, post-market evaluation.
    "One-stop" services for drug development include new drug project research and activity screening, pharmaceutical research (including pilot production), pharmacology and toxicology research, production of clinical drugs and agent simulatant, clinical trials, clinical data management and statistical analysis, post-market evaluation.
    "One-stop" services for drug development include new drug project research and activity screening, pharmaceutical research (including pilot production), pharmacology and toxicology research, production of clinical drugs and agent simulatant, clinical trials, clinical data management and statistical analysis, post-market evaluation.
    "One-stop" services for drug development include new drug project research and activity screening, pharmaceutical research (including pilot production), pharmacology and toxicology research, production of clinical drugs and agent simulatant, clinical trials, clinical data management and statistical analysis, post-market evaluation.
    "One-stop" services for drug development include new drug project research and activity screening, pharmaceutical research (including pilot production), pharmacology and toxicology research, production of clinical drugs and agent simulatant, clinical trials, clinical data management and statistical analysis, post-market evaluation.
    "One-stop" services for drug development include new drug project research and activity screening, pharmaceutical research (including pilot production), pharmacology and toxicology research, production of clinical drugs and agent simulatant, clinical trials, clinical data management and statistical analysis, post-market evaluation.
    "One-stop" services for drug development include new drug project research and activity screening, pharmaceutical research (including pilot production), pharmacology and toxicology research, production of clinical drugs and agent simulatant, clinical trials, clinical data management and statistical analysis, post-market evaluation.
    Boji Medical Technology Co., Ltd.
    Boji Medical Technology Co., Ltd.(Boji for short, stock code: 300404), founded in 2002 and listed in Shenzhen GEM in 2015.
    Boji Medical Technology Co., Ltd.
    Boji Medical Technology Co., Ltd.(Boji for short, stock code: 300404), founded in 2002 and listed in Shenzhen GEM in 2015.
    Drug Efficacy and Screen
    Consulting Service
    Consulting service

    For more questions, please click "Consult Now", a professional consultant will answer your questions.


    Drug efficacy study is the first step in new drug development. The result of  the druggability study determines whether the new compound (or Chinese medicine prescription) is suitable for clinical trials. The design level of major efficacy studies depends on whether the new drug is justifiable.

    Boji has been engaged in new drug research and development for nearly two decades. Boji has a professional research team in efficacy study and drug screening. Five major efficacy evaluation and screening platforms have been established for anti-tumor drugs, cardiovascular and cerebrovascular drugs, endocrine and metabolic drugs, nervous system drugs and external preparations (including nebulized inhalation preparations). In addition, the team members also have research experience in the diseases of the digestive system, respiratory system, bone joint system, urogenital system and other diseases.

    Boji always adheres to the new drug evaluation concept of "quality management and academic emphasis", and continuously strengthens the construction and implementation of quality management systems. At the same time, Boji pays attention to academic research, exploring new methods of animal models and seeking ways to control the quality of experiments. Boji will regularly provide research and management personnel the opportunity to participate in internal and external trainings, continuously improve professionalsm and strive to provide customers with more professional R & D services.

    Five pharmacodynamics test platforms

    Anti-tumordrug development platform


    In vitro anti-tumor test

    This platform can perform in vitro activity measurement of tumors such as lung cancer, liver cancer, stomach cancer, colon cancer, breast cancer, pancreatic cancer, ovarian cancer and leukemia.

    In vivo anti-tumor test

    The CDX model is the most commonly used method for screening anti-tumor drugs. In addition to conducting research on solid tumors and ascites tumors in nude mice or ordinary mice, this platform also conducts observation of life-cycle tests of tumor-bearing mice and explores new treatment options for tumors. The center is building a PDX model platform and plans to find biomarkers, distinguish treatment-sensitive patient groups, accelerate the drug development process and improve the success rate of drug clinical trials. The platform provides technical services for bone cancer, lung cancer and gynecological cancer.

    Study on Antitumor Mechanism

    Cell cycle research: block cell cycle, inhibit telomerase activity and interfere with cell signaling pathways;

    Apoptosis: expression of apoptotic genes, activation of apoptotic signaling pathways, nuclear factor kB;

    Cytotoxicity research: Inhibition of cell microtubule polymerization, tumor cell DNA replication, RNA interference, translation; free radicals and antioxidant effects, regulation of the immune system;

    Cell invasion and metastasis studies: Inhibition of proteolytic enzymes on degradation of basementand extracellular membrane, anti-cell adhesion, inhibit neovascularization, plasmin and plasminogen activation.


    Cardio-cerebralvascular research and development platform


    Heart failure

    Drug-induced acuteor chronic heart failure model, surgical myocardial ischemia acute or chronic heart failure model, aortic stenosis chronic heart failure model.


    Ischemic heartdisease (coronary heart disease)

    Drug-induced myocardial rat ischemia model, coronary artery ligated rat, dog and pig myocardial ischemia or infarction model, cardiac hemodynamics and myocardial oxygen consumption test, isolated heart flow test, in vitro cultured myocardial cell injury model etc.


    Ischemiccerebrovascular disease (stroke)

    Rat middle cerebral artery occlusion model (MCAO), chemically induced cerebral thrombosis model, carotid artery ligation cerebral ischemia reperfusion model, whole brain ischemia model, in vitro cultured neuronal cell injury model, antithrombotic test animal model.


    Hypertension

    Renal hypertension model (RHD, DHR), endocrine hypertension model CDOC + nephrectomy),spontaneously hypertensive rats (SHR), stroke-prone spontaneous hypertensive rats (SHRsp), etc.


    Atherosclerosis

    Atherosclerosis model (high-fat feed method, surfactant method, immunological method, etc.)



    Endocrine and Metabolic Drug Development Platform


    diabetes

    Chemical type 1 diabetes model (streptozotocin, tetraoxopyrimidine), experimental obese type 2 diabetes rat / mice model (db / db mice, kk mice, GK rats, etc.), impaired glucose tolerance mouse model, the mechanism of hypoglycemic effect study.


    Complications ofdiabetes

    Diabetic nephropathy rat model, diabetic neuropathy rat model, diabetic lipid metabolism abnormal model, etc.

    Obesity

    Spontaneous genetic obesity model, high diet-induced obesity model, bilateral ovariectomized obese female eye model, hypothalamic feeding central nervous injury obesity model (sodium glutamate, gold sulfur glucose).

    Hyperlipidemiamodel

    Hyperlipidemia model induced by high-fat feed, hyperlipidemia model induced by high-fatemulsion gavage, transgenic animal model.

    Fatty liver

    Hyperlipidemia for the main fatty liver model (obese rats, fed with high fat), impairment of liver VDLD synthesis and secretion for the main fatty liver model in rats (induced by ethionine and tetracycline), inhibition of fatty acid oxidized lipids inanti-hepatic model (induced by carnitine, carbon tetrachloride, alcohol), multiple factors replicate rat fatty liver model.

    Gout

    Mouse hyperuricemia model, rat hyperuricemia model, rat foot swelling model induced by urate crystals, rat or rabbit hyperuricemia with urate crystal-inducedarthritis model, rat hyperuricemia and urinary nephropathy model.


    Neurological Drug DevelopmentPlatform


    Pain

    Chemical stimulation method (twisted body method, formalin method), thermal stimulation method (hot plate method, radiation thermal stimulation method), electrical stimulation method (rat tail flick method), mechanical stimulation method (mouse tail root compression method), chronic pain model.

    Fever

    Infectious fever(bacteria, endotoxin, yeast), non-infectious fever (carrageenan, etc.).

    Aging or dementia

    Natural aging model, rapid aging SAMP8 mouse model, APP / PS1 double transgenic mouse model, thymectomy model, D-galactose aging model, drug-induced dementia model, transgenic animal dementia (AD) model, etc.

    Parkinson

    6-OHDA induction model, MPTP induction model, transgenic model.

    Depression

    Stress model (forced swimming experiment, tail suspension experiment, acquired helplessness model, chronic unpredictable stress model); Drug model (reserpine reversal, high-dose apomorphine antagonism, 5-HTP enhancement, yohimbine toxicity enhancement).


    Externalpreparation development platform (including inhaledpreparations)


    Burn (scald)

    Flame burn model, hot water burn model, thermal contact burnmodel, experimental electric burn model, experimental phosphorus burn model , , old burn model. Experimental animals can be mice, rats, rabbits, mini-pigs.

    Eczema, itchyskin

    Eczema models induced by dinitrofluorobenzene (DNFB) or dinitrooxybenzene (DNCB) (mouse, rat,guinea pig), histamine itch test, dextran itch test, mouse auricle swelling test, capillary permeability test, guinea pig passive skin allergy test, etc.

    Otitis media,Otitis media

    Combined bacterial external ear canalitis rat or rabbit model, fungal external otitis inflammation guinea pig or rabbit model, bacterial otitis media rat model, bacterial otitis media rabbit model, etc.

    Oral ulcer

    Oral mucosal ulcer model in rabbits induced by acetic acid, oral ulcer model in guinea pigs with electrical injury.

    Respiratory diseases (aerosolized inhalation preparation)

    Animal models of nebulized inhalation for the treatment of respiratory diseases, including cough test, asthma test, phlegm test, COPD animal model, mouse bacterial lung infection test.


    Other drugdevelopment platforms


    Diseases of the digestive system

    Liver fibrosis, fatty liver model, gastric ulcer model, diarrhea model, irritable bowel syndrome(IBS) model, histamine gastric acid secretion model.

    Respiratory diseases

    Cough test (chemical, mechanical, electrical), Flat-mouth test (tracheal spiral stripmethod, allergen-induced asthma method), Phlegm test (tracheal phenol redmethod, capillary glass tube method, tracheal cilia movement method), chronic bronchitis model, chronic obstructive pneumonia model, emphysema model, airway hyperresponsiveness model.

    Bone and JointDiseases

    Rheumatoid arthritis model, osteoarthritis model, osteoporosis model, fracture model.

    Diseases of thegenitourinary system

    Chronic renal failure rat model, anterior adenitis model, castrated animal model, sexual dysfunction, plough, animal model of pelvic inflammatory disease, etc.


    Instrument and equipment


    Cardiovascular and cerebrovascular pharmacology

    BIOPAC 16-channel physiological recording system, transonic ultrasound Doppler flow meter, MYLAB40HD color ultrasound, blood oxygen analysis, etc.

    Respiratory system

    Dr. Shanghai Mobile Datum's spontaneous activity video analysis system, jump platform(shuttle, avoid dark) video analysis system, 6-channel universal turn stick instrument, TM-vision behavioral test workstation, Morris water maze system,etc.

    Respiratory system

    Lung function tester, YLS-8A multifunctional cough inducer and asthma meter, etc.

    Molecular biology

    USA / Beckman CoulterCy to FLEXBL flow cytometer, SV-8 isolated tissue and organ constant temperature perfusion system, Epoch2 microplate reader, ELX-808I1U microplate reader, BIOBASE-9621 automatic plate washer, CountstarlC1000 cell counter,cence TGL-16M high-speed refrigerated centrifuge, UW620H / Shimadzu one thousandth electronic balance, cell culture incubator, etc.


    • Phone:400-0020-628
    • Address:Clinical Center:7th Floor, Building A, Vanke Cloud Plaza, 1933 Huaguan Road, Tianhe District, Guangzhou / Laboratory Address:No.62,Nanxiang One Road,Huangpu Disrict,Guangzhou
    Copyright ? Boji Medical Technology Co., Ltd. All Rights Reserved 粵ICP備13039920號 (粵)—非經營性—2020-0084 Powered by vancheer
    Copyright ? Boji Medical Technology Co., Ltd. All Rights Reserved 粵ICP備13039920號 (粵)—非經營性—2020-0084 Powered by vancheer
    JAPAN18XXXXHD VIDEOS日本